By
Prof. Alan Talevi (PhD)
| Reviewed by
Prof. Alan Talevi (PhD)
Page last updated:
07/02/2024 |
Next review date:
07/02/2026
verified
The contents of this article are fact-based except otherwise stated within the article.
close
Author bio
Prof Alan Talevi (PhD)
Drug discovery and development Scientist
Prof Dr Alan Talevi is a Pharmacist with expertise in the fields of Medicinal Chemistry, Drug Discovery and Development, and Pharmacokinetics. He writes and reviews content related to Pharmacology and Pharmacokinetics.
Dr Alan Talevi’s Highlights:
Researcher at the Argentinean Council of Scientific and Technical Research (CONICET). Full Professor of Biopharmacy at the University of La Plata.
PhD in Exact Sciences with a focus on Medicinal Chemistry at the University of La Plata/ Argentina. Pharmacist and Bachelor in Pharmacy at the University of La Plata/ Argentina.
Professional Experience:
After obtaining his PhD, Dr Alan Talevi obtained a permanent position at the Argentinean National Council of Scientific and Technical Research (CONICET). He has taught courses on the Pharmacy career at the University of La Plata for more than 20 years,
Dr Alan Talevi has acted as PI in more than 10 national and international scientific grants.
Dr Alan Talevi has also acted as an external reviewer for several agencies, universities and organizations from the UK, Belgium, Poland, Argentina, Uruguay, Chile, Perú and Brazil. He is a member of the editorial board of several journals: Editorial Board Member of Current Therapeutic Research (Elsevier) and the Latin American Journal of Pharmacy, Reviewing Editor for eLife, and Associate Editor for Frontier in Natural Products. He has edited several books, including the ADME Encyclopedia (Springer Nature’s Major Reference Works series).
Dr Alan Talevi participated as a member of the examination board for more than 20 Ph.D. exams at several universities, including the University of La Plata, the University of Buenos Aires, the University of Rosario, the University of San Martín, the University of Quilmes, and Rhodes University. He has supervised 6 approved PhD thesis.
Education:
2004 Bachelor in Pharmacy at the University of La Plata, Argentina
2007 PhD in Exact Sciences at the University of La Plata, Argentina
2023 Bachelor in Creative Writing at the National University of Arts, Argentina
The main recent publications of Dr. Alan Talevi (among more than 100) are:
1. |
Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects.
Talevi A.
Methods Mol Biol. 2024;2714:1-20. |
2. |
Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies.
Muraca G, Ruiz ME, Gambaro RC, Scioli-Montoto S, Sbaraglini ML, Padula G, Cisneros JS, Chain CY, Álvarez VA, Huck-Iriart C, Castro GR, Piñero MB, Marchetto MI, Alba Soto C, Islan GA, Talevi A.
Beilstein J Nanotechnol. 2023 Jul 28;14:804-818. |
3. |
Synthesis and biological evaluation of new antiseizure compounds derived from valproic acid.
Garofalo FM, Sbaraglini ML, Barrionuevo EM, Peralta E, Bonifazi EL, Talevi A, Gavernet L.
Future Med Chem. 2023 May;15(9):735-743. |
4. |
Making the most effective use of available computational methods for drug repositioning.
Prada Gori DN, Alberca LN, Talevi A.
Expert Opin Drug Discov. 2023 May;18(5):495-503. |
5. |
A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity.
Llanos MA, Alberca LN, Ruiz MD, Sbaraglini ML, Miranda C, Pino-Martinez A, Fraccaroli L, Carrillo C, Alba Soto CD, Gavernet L, Talevi A.
J Comput Aided Mol Des. 2023 Feb;37(2):75-90. |
6. |
Identification of New Carbonic Anhydrase VII Inhibitors by Structure-Based Virtual Screening.
Gantner ME, Prada Gori DN, Llanos MA, Talevi A, Angeli A, Vullo D, Supuran CT, Gavernet L.
J Chem Inf Model. 2022 Oct 10;62(19):4760-4770. |
7. |
Novel Phenobarbital-Loaded Nanostructured Lipid Carriers for Epilepsy Treatment: From QbD to In Vivo Evaluation.
Scioli-Montoto S, Sbaraglini ML, Cisneros JS, Chain CY, Ferretti V, León IE, Alvarez VA, Castro GR, Islan GA, Talevi A, Ruiz ME.
Front Chem. 2022 Aug 17;10:908386. |
8. |
Structure-Based Virtual Screening Identifies Novobiocin, Montelukast, and Cinnarizine as TRPV1 Modulators with Anticonvulsant Activity In Vivo.
Llanos MA, Enrique N, Sbaraglini ML, Garofalo FM, Talevi A, Gavernet L, Martín P.
J Chem Inf Model. 2022 Jun 27;62(12):3008-3022. |
9. |
Antiseizure medication discovery: Recent and future paradigm shifts.
Talevi A.
Epilepsia Open. 2022 Aug;7 Suppl 1(Suppl 1):S133-S141. |
10. |
Tetracycline Derivatives Inhibit Plasmodial Cysteine Protease Falcipain-2 through Binding to a Distal Allosteric Site.
Hernández González JE, Alberca LN, Masforrol González Y, Reyes Acosta O, Talevi A, Salas-Sarduy E.
J Chem Inf Model. 2022 Jan 10;62(1):159-175. |
11. |
Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study.
Llanos MA, Gantner ME, Rodriguez S, Alberca LN, Bellera CL, Talevi A, Gavernet L.
J Chem Inf Model. 2021 Aug 23;61(8):3758-3770. |
12. |
Can drug repurposing strategies be the solution to the COVID-19 crisis?
Bellera CL, Llanos M, Gantner ME, Rodriguez S, Gavernet L, Comini M, Talevi A.
Expert Opin Drug Discov. 2021 Jun;16(6):605-612. |
13. |
Parabens inhibit hNaV 1.2 channels.
Enrique A, Martín P, Sbaraglini ML, Talevi A, Milesi V.
Biomed Pharmacother. 2020 Aug;128:110250. |
14. |
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions.
Auzmendi J, Palestro P, Blachman A, Gavernet L, Merelli A, Talevi A, Calabrese GC, Ramos AJ, Lazarowski A.
Front Behav Neurosci. 2020 Mar 17;14:32 . |
15. |
Machine Learning in Drug Discovery and Development Part 1: A Primer.
Talevi A, Morales JF, Hather G, Podichetty JT, Kim S, Bloomingdale PC, Kim S, Burton J, Brown JD, Winterstein AG, Schmidt S, White JK, Conrado DJ.
CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):129-142. |
16. |
Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics.
Talevi A, Bellera CL.
Expert Opin Drug Discov. 2020 Apr;15(4):397-401. |
17. |
Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
Sbaraglini ML, Bellera CL, Quarroz Braghini J, Areco Y, Miranda C, Carrillo C, Kelly J, Buchholz B, Gelpi RJ, Talevi A, Alba Soto CD.
Eur J Med Chem. 2019 Dec 15;184:111778. |
You can view some of his work below and links to his professional profile.
Researchgate: https://www.researchgate.net/profile/Alan-Talevi
Google Scholar: https://scholar.google.co.in/citations?user=TqFfWCsAAAAJ&hl=en
Scopus: https://www.scopus.com/authid/detail.uri?authorId=14833640500
Linkedin: https://www.linkedin.com/in/alan-talevi-8073571a/
close
Reviewer bio
Prof Alan Talevi (PhD)
Drug discovery and development Scientist
Prof Dr Alan Talevi is a Pharmacist with expertise in the fields of Medicinal Chemistry, Drug Discovery and Development, and Pharmacokinetics. He writes and reviews content related to Pharmacology and Pharmacokinetics.
Dr Alan Talevi’s Highlights:
Researcher at the Argentinean Council of Scientific and Technical Research (CONICET). Full Professor of Biopharmacy at the University of La Plata.
PhD in Exact Sciences with a focus on Medicinal Chemistry at the University of La Plata/ Argentina. Pharmacist and Bachelor in Pharmacy at the University of La Plata/ Argentina.
Professional Experience:
After obtaining his PhD, Dr Alan Talevi obtained a permanent position at the Argentinean National Council of Scientific and Technical Research (CONICET). He has taught courses on the Pharmacy career at the University of La Plata for more than 20 years,
Dr Alan Talevi has acted as PI in more than 10 national and international scientific grants.
Dr Alan Talevi has also acted as an external reviewer for several agencies, universities and organizations from the UK, Belgium, Poland, Argentina, Uruguay, Chile, Perú and Brazil. He is a member of the editorial board of several journals: Editorial Board Member of Current Therapeutic Research (Elsevier) and the Latin American Journal of Pharmacy, Reviewing Editor for eLife, and Associate Editor for Frontier in Natural Products. He has edited several books, including the ADME Encyclopedia (Springer Nature’s Major Reference Works series).
Dr Alan Talevi participated as a member of the examination board for more than 20 Ph.D. exams at several universities, including the University of La Plata, the University of Buenos Aires, the University of Rosario, the University of San Martín, the University of Quilmes, and Rhodes University. He has supervised 6 approved PhD thesis.
Education:
2004 Bachelor in Pharmacy at the University of La Plata, Argentina
2007 PhD in Exact Sciences at the University of La Plata, Argentina
2023 Bachelor in Creative Writing at the National University of Arts, Argentina
The main recent publications of Dr. Alan Talevi (among more than 100) are:
1. |
Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects.
Talevi A.
Methods Mol Biol. 2024;2714:1-20. |
2. |
Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies.
Muraca G, Ruiz ME, Gambaro RC, Scioli-Montoto S, Sbaraglini ML, Padula G, Cisneros JS, Chain CY, Álvarez VA, Huck-Iriart C, Castro GR, Piñero MB, Marchetto MI, Alba Soto C, Islan GA, Talevi A.
Beilstein J Nanotechnol. 2023 Jul 28;14:804-818. |
3. |
Synthesis and biological evaluation of new antiseizure compounds derived from valproic acid.
Garofalo FM, Sbaraglini ML, Barrionuevo EM, Peralta E, Bonifazi EL, Talevi A, Gavernet L.
Future Med Chem. 2023 May;15(9):735-743. |
4. |
Making the most effective use of available computational methods for drug repositioning.
Prada Gori DN, Alberca LN, Talevi A.
Expert Opin Drug Discov. 2023 May;18(5):495-503. |
5. |
A combined ligand and target-based virtual screening strategy to repurpose drugs as putrescine uptake inhibitors with trypanocidal activity.
Llanos MA, Alberca LN, Ruiz MD, Sbaraglini ML, Miranda C, Pino-Martinez A, Fraccaroli L, Carrillo C, Alba Soto CD, Gavernet L, Talevi A.
J Comput Aided Mol Des. 2023 Feb;37(2):75-90. |
6. |
Identification of New Carbonic Anhydrase VII Inhibitors by Structure-Based Virtual Screening.
Gantner ME, Prada Gori DN, Llanos MA, Talevi A, Angeli A, Vullo D, Supuran CT, Gavernet L.
J Chem Inf Model. 2022 Oct 10;62(19):4760-4770. |
7. |
Novel Phenobarbital-Loaded Nanostructured Lipid Carriers for Epilepsy Treatment: From QbD to In Vivo Evaluation.
Scioli-Montoto S, Sbaraglini ML, Cisneros JS, Chain CY, Ferretti V, León IE, Alvarez VA, Castro GR, Islan GA, Talevi A, Ruiz ME.
Front Chem. 2022 Aug 17;10:908386. |
8. |
Structure-Based Virtual Screening Identifies Novobiocin, Montelukast, and Cinnarizine as TRPV1 Modulators with Anticonvulsant Activity In Vivo.
Llanos MA, Enrique N, Sbaraglini ML, Garofalo FM, Talevi A, Gavernet L, Martín P.
J Chem Inf Model. 2022 Jun 27;62(12):3008-3022. |
9. |
Antiseizure medication discovery: Recent and future paradigm shifts.
Talevi A.
Epilepsia Open. 2022 Aug;7 Suppl 1(Suppl 1):S133-S141. |
10. |
Tetracycline Derivatives Inhibit Plasmodial Cysteine Protease Falcipain-2 through Binding to a Distal Allosteric Site.
Hernández González JE, Alberca LN, Masforrol González Y, Reyes Acosta O, Talevi A, Salas-Sarduy E.
J Chem Inf Model. 2022 Jan 10;62(1):159-175. |
11. |
Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study.
Llanos MA, Gantner ME, Rodriguez S, Alberca LN, Bellera CL, Talevi A, Gavernet L.
J Chem Inf Model. 2021 Aug 23;61(8):3758-3770. |
12. |
Can drug repurposing strategies be the solution to the COVID-19 crisis?
Bellera CL, Llanos M, Gantner ME, Rodriguez S, Gavernet L, Comini M, Talevi A.
Expert Opin Drug Discov. 2021 Jun;16(6):605-612. |
13. |
Parabens inhibit hNaV 1.2 channels.
Enrique A, Martín P, Sbaraglini ML, Talevi A, Milesi V.
Biomed Pharmacother. 2020 Aug;128:110250. |
14. |
Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions.
Auzmendi J, Palestro P, Blachman A, Gavernet L, Merelli A, Talevi A, Calabrese GC, Ramos AJ, Lazarowski A.
Front Behav Neurosci. 2020 Mar 17;14:32 . |
15. |
Machine Learning in Drug Discovery and Development Part 1: A Primer.
Talevi A, Morales JF, Hather G, Podichetty JT, Kim S, Bloomingdale PC, Kim S, Burton J, Brown JD, Winterstein AG, Schmidt S, White JK, Conrado DJ.
CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):129-142. |
16. |
Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics.
Talevi A, Bellera CL.
Expert Opin Drug Discov. 2020 Apr;15(4):397-401. |
17. |
Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.
Sbaraglini ML, Bellera CL, Quarroz Braghini J, Areco Y, Miranda C, Carrillo C, Kelly J, Buchholz B, Gelpi RJ, Talevi A, Alba Soto CD.
Eur J Med Chem. 2019 Dec 15;184:111778. |
You can view some of his work below and links to his professional profile.
Researchgate: https://www.researchgate.net/profile/Alan-Talevi
Google Scholar: https://scholar.google.co.in/citations?user=TqFfWCsAAAAJ&hl=en
Scopus: https://www.scopus.com/authid/detail.uri?authorId=14833640500
Linkedin: https://www.linkedin.com/in/alan-talevi-8073571a/
In this short article, we will answer the question “Should Abilify be taken in the morning?”. We will discuss the effects that Abilify may have on your sleep-wake cycle and metabolism and the advantages of taking Abilify in the morning. Finally, we will provide some general advice that may be helpful if you are taking Abilify.
Should Abilify be taken in the morning?
In general, Abilify (also known as Aripiprazole) should preferably be taken in the morning to mitigate the impact of this medication on your 24-hour cycle and metabolism. However, taking Abilify at night may be preferable for some individuals.
Abilify is used to treat a variety of conditions, including psychosis, depression, bipolar disorder, Tourette’s syndrome, and irritation in people with autism or autism spectrum disorders. It is a prescription medicine that should only be taken under the guidance of a doctor.
You should be open with your doctor regarding any treatment-related issues that you may experience while taking Abilify. Do not make changes to the way you take your Abilify without prior consultation with your doctor.
What are the effects of Abilify on your sleep-wake cycle?
Circadian rhythms are 24-hour cycles that are part of your body’s internal clock, coordinating several processes and functions. The sleep-wake cycle is possibly the most clear example of a circadian rhythm. During the daytime, light sends signals to your internal clock in the brain, which produces alertness. In the evening, in contrast, the brain produces signals that induce restorative sleep.
In some people, however, the internal clock is not properly aligned with the light-dark cycle, which results in sleepiness in the daytime and insomnia at bedtime. In particular, if you have a psychiatric condition or mood disorder you are more likely to experience disruptions in your sleep-wake cycle (1).
Several reports suggest that Abilify may help correct your internal clock, thus normalizing your sleep-wake pattern (2-5). However, in some individuals, Abilify may cause tiredness or sleepiness (2, 6), potentially interfering with daytime alertness. This is more likely to occur if you are taking other medications to treat depression or mood disorders together with Abilify. Alcohol intake may also enhance this side effect.
Sleepiness seems also to be more frequent with high doses of Abilify and may compromise the ability to perform activities that require motor coordination, such as driving or cycling.
What are the effects of Abilify on your metabolism?
Antipsychotic medications may frequently disturb your metabolism. Between 37 and 63% of people who use antipsychotic medications develop metabolic syndrome (7), which may involve weight gain, elevated blood pressure, abnormal levels of lipids (such as cholesterol) in the blood, and increased risk for diabetes.
Abilify is often considered “metabolically neutral” because it has fewer side effects on your metabolism than other antipsychotics (8, 9). However, it was shown in a double-blind study involving ten subjects that it can have a modest and negative effect on insulin sensitivity (10), and some impact on other metabolic parameters (9).
In a small-scale study comparing the metabolic effects of Abilify taken in the morning or at bedtime, it was found that taking Abilify in the evening slightly decreases HDL (“good cholesterol”) (9). This effect was not observed in the study participants who took Abilify in the morning.
Since high levels of “good” cholesterol can protect you from heart and stroke, this can be considered a negative effect of taking Abilify at night.
What are the benefits of taking your Abilify in the morning?
The main benefits of taking your Abilify in the morning can be summarized as follows:
- Evidence suggests that Abilify will have fewer negative effects on your metabolism if you consume it in the morning.
- For people who experience insomnia after taking Abilify, using this medication in the morning may be less disruptive to their sleep patterns.
- People tend to miss fewer morning medications than evening medications (11).
Moreover, morning activities such as breakfast or normal caffeine intake do not seem to interact negatively with Abilify. However, if you experience somnolence/sedation after taking Abilify, it may be better to take Abilify in the evening. This is more likely to occur if you use high doses of Abilify or when you begin taking Abilify.
Is there any advice to consider if you are taking Abilify?
Some important advice if you are taking Abilify includes the following:
- Brain medications that cause reduced alertness can increase the risk associated with complex tasks such as driving a vehicle or operating machinery. You should avoid dangerous activities until you have verified how Abilify affects you. Alcohol intake can worsen this side effect.
- The metabolic side effects of Abilify may be mitigated by following a healthy diet and exercising regularly.
- It is important to take antipsychotic medications regularly and adhere to the dosing scheme specified by your doctor. Avoid skipping your daily Abilify dose. D
- If you are replacing another psychiatric medication with Abilify, do not quit your prior medication suddenly as you may decompensate.
- Do not change the dose or the time of your daily Abilify or stop taking Abilify without medical supervision.
Conclusions
From my professional perspective, taking Abilify in the morning may be better than in the evening, as it may be less disruptive to your metabolism and sleep pattern. However, some patients may experience somnolence after taking Abilify. For these people, taking Abilify at bedtime may be preferable. In any case, do not modify the dose or time of Abilify without medical supervision.
Thanks for your feedback!
References
2.-
Omori Y, Kanbayashi T, Sagawa Y, Imanishi A, Tsutsui K, Takahashi Y, Takeshima M, Takaki M, Nishino S, Shimizu T. Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation. Neuropsychiatr Dis Treat. 2018 May 18;14:1281-1286. doi: 10.2147/NDT.S158865. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965391/
3.-
Matsui K, Takaesu Y, Inoue T, Inada K, Nishimura K. Effect of aripiprazole on non-24-hour sleep-wake rhythm disorder comorbid with major depressive disorder: a case report. Neuropsychiatr Dis Treat. 2017 May 19;13:1367-1371. doi: 10.2147/NDT.S136628. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449127/
4.-
Li R, Masuda K, Ono D, Kanbayashi T, Hirano A, Sakurai T. Aripiprazole disrupts cellular synchrony in the suprachiasmatic nucleus and enhances entrainment to environmental light-dark cycles in mice. Front Neurosci. 2023 Aug 9;17:1201137. doi: 10.3389/fnins.2023.1201137. Available from:
https://www.frontiersin.org/articles/10.3389/fnins.2023.1201137/full
7.-
Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010 Sep;71(9):1138-44. doi: 10.4088/JCP.09m05159gre. Available from:
https://www.psychiatrist.com/jcp/metabolic-syndrome-patients-enrolled-clinical-trial/
8.-
Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, Ochoa D, Navares-Gómez M, Santos-Molina E, Pintos-Sánchez E, Abad-Santos F. Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: Association with pharmacogenetics. Adv Ther. 2021 Feb;38(2):1035-1054. doi: 10.1007/s12325-020-01566-w. Available from: https://link.springer.com/article/10.1007/s12325-020-01566-w